Abstract
Greystone Research Associates is pleased to announce the publication of a new
market study. Oral Transmucosal Drug Delivery: Products, Players, Markets
and Forecasts is a comprehensive evaluation and analysis of the
technology, products and participants providing the driving force behind this
evolving segment of the healthcare sector.
The study is designed to provide drug company decision makers, drug delivery
developers, device designers, healthcare marketers, and supply chain
participants with a detailed understanding of the products, markets and
commercial opportunities for drug delivery films, sprays, lozenges, wafers and
orally dissolvable tablets that are designed to be administered into the oral
cavity and be absorbed systematically via the oral mucosa. Provider
organization business managers, healthcare administrators and investors will
also benefit from this study.
Safety, Compliance and Oral Drug Technology
In their search for alternative delivery methods that will enhance compliance
and improve safety, drug developers and researchers are discovering that the
permeability of mucous membranes provides a convenient route for the systemic
delivery of new and existing therapeutic drugs. Transmucosal delivery offers
the potential for once daily dosing of oral drugs and avoids the effects of
first pass metabolism. On the provider side, the development of alternative
methods of drug administration has improved the ability of physicians to
manage specific problems. Practitioners now recognize the rapid onset,
relative reliability, and the general lack of patient discomfort when drugs
are administered by the transmucosal route. We expect this market to
experience healthy growth through 2016 as absorbable solid dosage technology
is applied to existing drugs and as absorbable formulations become an
important route of administration for an increasing number of new NCEs. Growth
in this sector will also be driven by the pressure to extend market protection
for numerous existing drugs with soon-to-expire patents.
Highlights
- Analyzes and evaluates oral transmucosal drug delivery technology
platforms and their impact on the market
- Analyzes oral transmucosal drug products and pipeline product candidates
- Provides assessments of key oral transmucosal drug therapeutic categories
- Provides market data and forecasts to 2016
- Profiles market participants, their product development activities and
strategies
Methodology
Research methodology is based on primary research in the form of in-depth
interviews with key market participants, technology developers, distributors,
industry experts, and market influencers, a list that includes regulatory
officials, industry trade groups, and materials standards organizations.
Primary data is evaluated and normalized against secondary sources including
trade journal articles, technical literature, industry publications, company
data sheets and published information, and statistical data from government
agencies and trade associations.
Forecasts and projections of market demand and future market activity are
derived using standard modeling and statistical techniques.
About Greystone Associates
Greystone Associates is a medical technology consulting firm focused on the
areas of medical market strategy, product commercialization, venture
development, and market research. We assist medical and healthcare market
participants in achieving their business objectives through the creation of
detailed development strategies, product commercialization programs, and
comprehensive market and technology research and analysis.
Our market research publications are designed, researched and written to
provide timely and insightful information and data on focused market segments,
with the aim of providing market participants with the essential knowledge to
refine and execute their marketing plans and financial targets.
Table of Contents
Executive Summary
Drug Delivery Market Dynamics
- Evolution in Drug Development
- Market and Demand Drivers
- Shifting Patient Demographics
- The Impact of Generics
- Managed Care Initiatives
- Competitive Landscape
Competing Transmucosal Delivery Technologies
- Oral Sprays
- Buccal Films and Tablets
- Sublingual Films and Wafers
Commercial Transmucosal Formulation Platforms
- Adversa
- BEMA
- Bioadhesive Delivery System
- Corplex
- FluidCrystal
- Intravail
- Lauriad
- OraDisc
- OraVescent
- RapidMist
- Transmucosal Film
Oral Transmucosal Drug Technology Factors
- Absorption
- Bioavailability
- Adhesion
- Pharmacokinetics
FDA-Approved Oral Transmucosal Products
- Asenapine
- Buprenorphine (3 products)
- Ergotamine
- Fentanyl (8 products)
- Hydergine
- Isosorbide dinitrate (2 products)
- Miconazole
- Nitroglycerin (3 Products)
- Ondansetron
- Testosterone
- Zolpidem (3 products)
- Zuplenz
Important Pipeline Product Candidates
- Agomelatine
- ALKS 5461
- Buprenorphine
- Buprehorphine
- Buprenorphine
- Cannabinoid
- Desmopressin
- Fentanyl
- Fentanyl
- Granisetron
- Insulin
- Ramelteon
- Sufentanil
- Sumatriptan
- Zolpidem
- Zolpidem
Market Assessments & Forecasts
- Addiction
- Anti-infectives
- Cardiology
- Diabetes
- Immunology
- Infectious Disease
- Neurology
- Oncology
- Pain Management
- Sexual Health
- Vaccines
Market Factors
- Formulations and Proprietary Platforms
- Government Regulations
- Patent Expiration and Rx-to-OTC Switching
Company Profiles
Oral Transmucosal Drug Delivery: Products, Players, Markets & Forecasts published by Greystone Research Associates in June 1, 2012. This report price starts from US $ 3850.
The contents of this page may be different from the latest version. Please contact us for details.
